Melissa Montez

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US

Pankit Vachhani, Evelyn M. Flahavan, Tao Xu et al. · The Oncologist · 2022 · 47 citations · Full text

Medicine, Oncology, Pharmacology +16

Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting

Anda Gershon, Esprit Ma, Tao Xu et al. · Clinical Lymphoma Myeloma & Leukemia · 2023 · 21 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +3

Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study

Keith W. Pratz, Courtney D. DiNardo, Dominik Selleslag et al. · Blood · 2020 · 17 citations

Medicine, Hematology, Pharmacotherapy +11

Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective

Keith W. Pratz, Xinglei Chai, Jipan Xie et al. · PharmacoEconomics · 2022 · 14 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +15